When a trial publishes with a critical comment and the authors’ reply printed alongside it, the journal is signaling that the findings drew immediate scrutiny. That is what happened with a new multicentre trial of prophylactic esketamine for postpartum depression. It reported that a single perioperative dose helped prevent the condition in first-time mothers, and it landed with a published critique and an author response in the same issue. The desk has deprioritized the esketamine-postpartum efficacy headlines, which have accumulated inconclusively for years. This one is worth surfacing not for the result but for the argument, because the objections are the two methodological problems that recur across this entire class of drug.
The trial
Across three academic hospitals, the investigators randomized first-time mothers scheduled for elective caesarean delivery, screened as not prenatally depressed using a low threshold on the Edinburgh scale, to either a single sub-anesthetic dose of esketamine followed by esketamine as an add-on to 24-hour patient-controlled intravenous analgesia, or to saline. The primary outcome was the incidence of postpartum depression over the months following delivery, and the authors concluded that esketamine was relatively safe and reduced it. This is a prevention study, not a treatment one: the question is whether a one-time perioperative drug can keep relatively low-risk women from developing postpartum depression in the first place.
The first objection: the blind
Esketamine produces noticeable acute neuropsychiatric effects, dizziness, dissociation, perceptual changes, that a saline control does not. When the active arm reliably experiences sensations the placebo arm never feels, patients, and sometimes the people assessing them, can infer which group they are in, and that knowledge contaminates a subjective, self-reported outcome like a depression-screening score. This is functional unblinding, and it is the same problem the desk has tracked through the psychedelic trials, through the accelerated-TMS sham question, and through the lysergide program that deliberately built a low-dose active control to fight it. A postpartum prevention trial that pairs a perceptible active drug with a questionnaire endpoint is squarely exposed to it, and the published critique pressed on exactly this point, citing a markedly higher rate of transient neuropsychiatric adverse events in the esketamine arm. If the women who got the drug could tell, the apparent benefit may be partly expectancy rather than pharmacology.
The second objection: the confound
The esketamine was not given in isolation. It was delivered in part as an adjunct to patient-controlled analgesia, and esketamine is itself an analgesic. Better postoperative pain control can lift mood and lower depression-screening scores on its own, which means the trial’s apparent preventive effect is entangled with its pain-relieving effect. The exchange between critic and authors turns substantially on this: whether the reduction in postpartum depression reflects a genuine, structural antidepressant action or a downstream consequence of short-term opioid-sparing analgesia. Disentangling a mood mechanism from a pain mechanism, when the same drug does both and is dosed through the analgesia pump, is genuinely difficult, and this design does not cleanly separate them.
Why this is the angle worth taking
The esketamine-for-postpartum literature is large, mixed, and dominated by perioperative trials whose results contradict one another, with meta-analyses leaning positive, individual randomized trials disagreeing, and effects that often look transient. Adding one more efficacy headline to that pile tells a reader very little. What the published exchange does is model the correct way to read these studies: a dramatic prevention claim, made in women who were not depressed to begin with, measured by a subjective screen, using a drug whose side effects can break the blind and whose analgesic action confounds the endpoint, has to be read with both of those problems held in view. The comment and reply are the field doing that work in real time, which is more useful to follow than any single point estimate.
The caveats
This is not evidence that esketamine fails to prevent postpartum depression. The literature is genuinely contested, and several trials are positive. The critique is a single published comment, and the authors defended their design in their reply; the desk is not adjudicating who is right. And prevention in low-risk women is a distinct question from treating diagnosed postpartum depression or major depression, where the evidence base and the stakes differ. The point here is the methodological terrain, not a verdict on the drug.
The frame
The desk’s standing read on the esketamine-postpartum cluster has been that the efficacy headlines outrun the evidence. A trial that publishes with its own rebuttal attached is, in effect, the cluster conceding the point. The two objections, a blind the drug may have broken and a benefit braided into pain relief, are not unique to obstetric care. They are the recurring obstacles to believing any subjective endpoint produced by a drug the patient can feel. The thing to watch is whether the next wave of trials in this space designs around them, with active controls and analgesia-matched comparison arms, or keeps generating results that need a comment printed next to them.